Cargando…

Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis

Single cell technologies allow the interrogation of tumor heterogeneity, providing insights into tumor evolution and treatment resistance. To better understand whether circulating tumor cells (CTCs) could complement metastatic biopsies for tumor genomic profiling, we characterized 11 single CTCs and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rothé, Françoise, Venet, David, Peeters, Dieter, Rouas, Ghizlane, Rediti, Mattia, Smeets, Dominiek, Dupont, Floriane, Campbell, Peter, Lambrechts, Diether, Dirix, Luc, Sotiriou, Christos, Ignatiadis, Michail
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256697/ https://www.ncbi.nlm.nih.gov/pubmed/35790747 http://dx.doi.org/10.1038/s41523-022-00445-7

Ejemplares similares

Circulating Tumor DNA to Interrogate the Safety of Letrozole-Associated Controlled Ovarian Stimulation for Fertility Preservation in Breast Cancer Patients
por: Rothé, Françoise, et al.
Publicado: (2021)

Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome
por: Venet, David, et al.
Publicado: (2020)

Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges
por: Wang, Xiaoxiao, et al.
Publicado: (2023)

Timing evolution of lobular breast cancer through phylogenetic analysis
por: Fimereli, Danai, et al.
Publicado: (2022)

Erratum: Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations
por: Brown, David, et al.
Publicado: (2017)

Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations
por: Brown, David, et al.
Publicado: (2017)

CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial
por: Rothé, Françoise, et al.
Publicado: (2019)

Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach
por: Bareche, Yacine, et al.
Publicado: (2019)

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
por: Bareche, Y, et al.
Publicado: (2018)

HER2-Positive Circulating Tumor Cells in Breast Cancer
por: Ignatiadis, Michail, et al.
Publicado: (2011)

SYST-27 INTERROGATION OF THE TUMOR IMMUNE MICROENVIRONMENT REVEALS DISTINCT IMMUNOSUPPRESSIVE LANDSCAPES IN GLIOBLASTOMA
por: Weng, Linqian, et al.
Publicado: (2023)

Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis
por: Azim, Hatem A., et al.
Publicado: (2013)

Correction: Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis
por: Azim, Hatem A., et al.
Publicado: (2013)

Phospholipase C gamma 1 (PLCG1) R707Q mutation is counterselected under targeted therapy in a patient with hepatic angiosarcoma
por: Prenen, Hans, et al.
Publicado: (2015)

FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
por: Gombos, Andrea, et al.
Publicado: (2021)

Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
por: Gombos, Andrea, et al.
Publicado: (2022)

Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer
por: Nguyen, Bastien, et al.
Publicado: (2019)

Global MicroRNA Expression Profiling Identifies MiR-210 Associated with Tumor Proliferation, Invasion and Poor Clinical Outcome in Breast Cancer
por: Rothé, Françoise, et al.
Publicado: (2011)

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
por: Agostinetto, Elisa, et al.
Publicado: (2021)

Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer
por: Sonnenblick, Amir, et al.
Publicado: (2015)

Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology
por: Fumagalli, Debora, et al.
Publicado: (2014)

Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting
por: Peeters, D J E, et al.
Publicado: (2013)

Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer
por: Lambrechts, Sandrina, et al.
Publicado: (2015)

Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations
por: Nguyen, Bastien, et al.
Publicado: (2018)

Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials
por: Rediti, Mattia, et al.
Publicado: (2023)

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
por: Raspé, Eric, et al.
Publicado: (2017)

The footprint of the ageing stroma in older patients with breast cancer
por: Brouwers, Barbara, et al.
Publicado: (2017)

A fuzzy gene expression-based computational approach improves breast cancer prognostication
por: Haibe-Kains, Benjamin, et al.
Publicado: (2010)

ESR1 mutations in metastatic lobular breast cancer patients
por: Desmedt, Christine, et al.
Publicado: (2019)

Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues
por: Toussaint, Jérôme, et al.
Publicado: (2009)

Low CD10 mRNA Expression Identifies High-Risk Ductal Carcinoma In Situ (DCIS)
por: Toussaint, Jérôme, et al.
Publicado: (2010)

Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial
por: Sonnenblick, Amir, et al.
Publicado: (2015)

pAKT pathway activation is associated with PIK3CA mutations and good prognosis in luminal breast cancer in contrast to p-mTOR pathway activation
por: Sonnenblick, Amir, et al.
Publicado: (2019)

Feasibility of developing reliable gene expression modules from FFPE derived RNA profiled on Affymetrix arrays
por: Jose, Vinu, et al.
Publicado: (2018)

Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients
por: Bohlok, Ali, et al.
Publicado: (2020)

Evaluation and consequences of heterogeneity in the circulating tumor cell compartment
por: Brouwer, Anja, et al.
Publicado: (2016)

No significant viral transcription detected in whole breast cancer transcriptomes
por: Fimereli, Danai, et al.
Publicado: (2015)

Interrogating the real /
por: Žižek, Slavoj
Publicado: (2006)

The Interrogation Mark
por: Brooke, Margaret C.
Publicado: (1925)

Interrogating Technology‐led Experiments in Sustainability Governance
por: Bernards, Nick, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_shpk38vpslsft03m8ms6vjotec